S. A. Signs, J. S. Tan, S. J. Salstrom, and T. M. File, Pharmacokinetics of imipenem in serum and 394 skin window fluid in healthy adults after intramuscular or intravenous administration, 1992.

, Antimicrob Agents Chemother, vol.36, pp.1400-1403

A. K. Majumdar, D. G. Musson, K. L. Birk, C. J. Kitchen, S. Holland et al., , p.397

G. Hesney, M. Xi, L. Li, S. X. Haesen, R. Blum et al., , p.398

P. Deutsch and J. D. Rogers, Pharmacokinetics of ertapenem in healthy young 399 volunteers, Antimicrob Agents Chemother, vol.46, pp.3506-3511, 2002.

D. Bono, V. Giacobbe, D. R. Marchese, A. Parisini, A. Fucile et al., , p.401

A. Arena, A. Molin, A. Martelli, A. Gratarola, C. Viscoli et al., , 2017.

, Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: 403 Should we get to the PK/PD root of the paradox? Virulence, vol.8, pp.66-73

C. C. Bulik and D. P. Nicolau, Double-carbapenem therapy for carbapenemase-Klebsiella, 2011.

, pneumoniae Antimicrob Agents Chemother, vol.55, pp.3002-3004

, Seventy-five years of researchon protein binding, Antimicrob Agents 407 Chemother, vol.62, pp.1663-1617, 2018.

V. Lorian and B. Atkinson, Abnormal forms of bacteria produced by antibiotics, Am J Clin 409 Pathol, vol.64, pp.678-688, 1975.

J. P. Andrade, L. De-macêdo-farias, J. F. Ferreira, and O. Bruna-romero,

D. Souza, M. A. De-carvalho, and K. V. Santos, Sub-Inhibitory Concentration of, p.412, 2016.

. Piperacillin-tazobactam, May be Related to Virulence Properties of Filamentous Escherichia 413 coli, Current microbiology, vol.72, pp.19-28

L. E. Adinolfi and P. F. Bonventre, Enhanced phagocytosis, killing, and serum sensitivity of 415, 1988.

, Escherichia coli and Staphylococcus aureus treated with sub-MICs of imipenem, Antimicrob, vol.416

, Agents Chemother, vol.32, pp.1012-1018

O. Zak and F. Kradolfer, Effects of subminimal inhibitory concentrations of antibiotics in 418 experimental infections, Rev Infect Dis, vol.1, pp.862-879, 1979.

I. O. Tornqvist, S. E. Holm, and O. Cars, Pharmacodynamic effects of subinhibitory antibiotic 420 concentrations, Scand J Infect Dis Suppl, vol.74, pp.94-101, 1990.

E. Ortega, M. A. De-pablo, A. M. Gallego, C. Alvarez, P. L. Pancorbo et al., & 422 de Cienfuegos, G. A. 1997. Modification of natural immunity in mice by 423 imipenem/cilastatin, The Journal of antibiotics, vol.50, pp.502-508

E. R. Ulloa, N. Dillon, H. Tsunemoto, J. Pogliano, G. Sakoulas et al., Avibactam, vol.425, 2019.

, Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate 426

, Immune Clearance. J Infect Dis, vol.220, pp.484-493

A. Pourbaix, F. Guérin, C. Burdet, L. Massias, F. Chau et al., , 2019.

, Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in 429

M. Pyelonephritis, Antimicrob Agents Chemother, vol.63, pp.903-922

K. Alexandre, F. Chau, F. Guérin, L. Massias, A. Lefort et al., , 2016.

, Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to 432

, KPC-producing Escherichia coli, J Antimicrob Chemother, vol.71, pp.1899-1904

R. Lepeule, E. Ruppé, P. Le, L. Massias, F. Chau et al., , 2012.

, Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due 435 to Escherichia coli harboring CTX-M-15-type extended-spectrum ?-lactamase, Antimicrob, vol.436

, Agents Chemother, vol.56, pp.1376-1381

L. Garcia-capdevila, C. López-calull, C. Arroyo, M. A. Moral, M. A. Mangues et al., , 1997.

, Determination of imipenem in plasma by high-performance liquid chromatography for 439 pharmacokinetic studies in patients, J Chromatogr B Biomed Sci App, vol.692, pp.127-132

T. Cavey, M. Ropert, M. De-tayrac, E. Bardou-jacquet, M. L. Island et al., , p.441

C. Bendavid, P. Brissot, and O. Loréal, Mouse genetic background impacts both on iron 442 and non-iron metals parameters and on their relationships, Biometals : an international 443 journal on the role of metal ions in biology, biochemistry, and medicine, vol.28, pp.733-743, 2015.